Mechanistic MIDD: Achieving Regulatory Success Through Strong Scientific Foundations
June 30, 2026 - 12:00 PM – 2:00 PM
CertaraJune 10, 2026
Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study
Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…
CertaraJune 9, 2026
Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies
Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.
CertaraJune 9, 2026
Beyond Compliance: What ICH M15 Means for the Future of Drug Development
Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…
CertaraJune 9, 2026
Applying AI-Driven Biosimulation to Drug Discovery
Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…
CertaraJune 2, 2026
Certainty US 2026 recap: advancing model-informed drug development right from the start
This blog shares the highlights of our US Certainty event and explains how AI-enabled approaches…
CertaraMay 26, 2026
Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…
CertaraMay 21, 2026
MIDD is Transforming Drug Development
Recorded live at the US Certainty 2026 client conference in Boston, Certara clients who are…
CertaraMay 21, 2026
How to Leverage PBPK Modeling and Simulation in Drug Research and Development
Learn how PBPK modeling and simulation in drug research and development reduces clinical burden, supports…
CertaraMay 12, 2026
